arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Medpace Holdings, Inc.

MEDP
$635.08 ▼ -21.33 (-3.25%) at close
Industrials ·Services-Commercial Physical & Biological Research ·USServices-Commercial Physical & Biological Research
47 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
89
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Medpace Holdings, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $17.7B
Dividend Yield —
Revenue Growth 8.5% ↘
Op. Margin 23.1% ↗
ROIC 22.8% ↘
FCF / Share $7.03 ↗
Trailing P/E 129.1x
Price / Book 30.4x
FCF Yield 1.1%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$716.00M
↑ +8.5% —
Net Income Profit after all expenses
$123.87M
↑ +8.1% —
Operating Margin Operating profit as % of sales
23.1%
↑ +11.4% 77th
FCF / Share Free cash flow per share
$7.03
↑ +43.4% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
82
Returns ↑
99
Cash Quality ↑
80

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 13 years · 47 quarters